Company invites individual and institutional investors as well as advisors to log on to VirtualInvestorConferences.com to view presentation
LAS VEGAS, June 5, 2017 /CNW/ -- CV Sciences, Inc. (OTCQB: CVSI), today announced that the June 1, 2017, presentation from Chief Financial Officer Joseph Dowling is now available for on-demand viewing at VirtualInvestorConferences.com.
CV Sciences, Inc.'s presentation will be available 24/7 for 90 days. Investors and advisors may download shareholder materials from the "virtual trade booth" for the next three weeks.
Recent Company Highlights
- CV Sciences, Inc. will meet with the Food and Drug Administration (FDA) in June 2017 to discuss its initial drug candidate (CVSI-007).
- In March 2017, CV Sciences, Inc. announced its first online education platform designed to enhance its brand education and advocacy through Experticity.
- CV Sciences. Inc. appointed Dr. Stephen M. Schmitz to its board of directors to help move its drug development program forward to commercialization.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California. Additional information is available at OTCMarkets.com or www.cvsciences.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.
Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
SOURCE CV Sciences, Inc.
For further information: Robert Haag, Managing Director, 866-976-4784, CVSI@irthcommunications.com; VirtualInvestorConferences.com, Bradley H. Smith, Director of Marketing, IR and Compliance Services, PR Newswire, +1.201.947.7157, firstname.lastname@example.org, http://www.cvsciences.com